Crown Bioscience acquires in vitro services provider OcellO

By The Science Advisory Board staff writers

May 5, 2021 -- Crown Bioscience, a JSR Life Sciences company, has acquired OcellO, a privately owned contract research organization in the Netherlands.

Through the acquisition, Crown will expand its portfolio of in vitro services, including integration of OcellO's high content imaging into Crown's in vitro and in vivo screening and immunotherapy assessment services.

The acquisition establishes CrownBio as the only global source licensed to offer customers specialized Hubrecht organoid technology (HUB) for drug development programs.

Under the terms of the acquisition, Leo Price, PhD, CEO and chief scientific officer at OcellO, will join Crown as senior vice president of in vitro to lead the company's in vitro business in the U.S. and Europe.

Financial terms of the acquisition were not disclosed.

Charles River, Cypre collaborate on in vitro services
Charles River Laboratories is joining forces with Cypre to advance the understanding of the tumor microenvironment and predict therapeutic efficacy. Charles...

Copyright © 2021

International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter